Bernardo Stein, MD
Interventional Cardiology · Clearwater, FLNPI 1952391518
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boston Scientific at 52.8% of the total. Reporting peaked in 2023 at $2,132 and has fallen 92.9% since, to $150 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 89 payments — averaging $72.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- AstraZeneca$2K
- Abiomed$367
- Shockwave Medical, Inc$163
- Medtronic$155
- Amgen$133
- plus $554 from 13 others
Across 110 payments — averaging $3003.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$233K
- Boston Scientific$97K
What the payments were for
- Consulting fees$3,82459%
- Food & beverage$2,57740%
- Education$501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $3,409 |
| AstraZeneca | 35 | $1,671 |
| Abiomed | 4 | $367 |
| Shockwave Medical, Inc | 3 | $163 |
| Medtronic(2 entities) | 3 | $155 |
| Amgen | 8 | $133 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Penumbra, Inc. | 1 | $100 |
| Abbott | 3 | $57 |
| Pfizer | 3 | $56 |
| Novartis | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 4 | $50 |
| Chiesi USA, Inc. | 2 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| AbbVie | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,363
- BRILINTA$1,074
- Impella$353
- OPTICROSS$170
- AVVIGO Guidance System$165
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$149
- Reveal LINQ$138
- Inspire$122
- Indigo$100
How this compares
$6,452 in reported general payments places this provider in the 40th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 363 | $426,041 |
| XareltoRivaroxaban | 111 | $138,867 |
| BrilintaTicagrelor | 105 | $86,438 |
| EntrestoSacubitril/Valsartan | 57 | $75,511 |
| Repatha SureclickEvolocumab | 46 | $59,265 |
| FarxigaDapagliflozin Propanediol | 40 | $43,215 |
| MounjaroTirzepatide | 18 | $24,193 |
| Praluent PenAlirocumab | 22 | $22,322 |
| JardianceEmpagliflozin | 13 | $18,543 |
| Rosuvastatin Calcium | 820 | $11,139 |
| Metoprolol Succinate | 683 | $8,692 |
| Ezetimibe | 284 | $6,822 |
| ClopidogrelClopidogrel Bisulfate | 644 | $6,782 |
| Atorvastatin Calcium | 777 | $6,746 |
| Amlodipine Besylate | 878 | $5,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $426,041363 claims |
| Johnson & JohnsonXarelto | $17 | $138,867111 claims |
| AstraZenecaBrilinta, Farxiga | $1,671 | $129,654145 claims |
| NovartisEntresto | $52 | $75,51157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Clearwater
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.